<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Akorn Inc. | Company News & Executive Profiles - AKRX | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/akorn+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Akorn Inc.]]></description>
	<s:counts start="0" returned="10" found="28" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Pequot Capital Sells the Bulk of Its Akorn Stake]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F144764-pequot-capital-sells-the-bulk-of-its-akorn-stake%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Market Folly submits: Given the fact that we already know Art Samberg's hedge fund Pequot Capital is winding down, we hesitated to even post this. But, we figured we'd quickly write it up anyways because Pequot will still have $1 billion or so invested within their Special Opportunities fund and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 23 Jun 2009 01:45:06 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/market+folly.html"><![CDATA[Market Folly]]></category>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Art Samberg's Pequot Capital Management: Portfolio Update]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F117287-art-samberg-s-pequot-capital-management-portfolio-update%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Market Folly submits: Art Samberg's hedge fund, Pequot Capital Management, has filed a few amended 13G's with the SEC, which details changes that were made to its portfolio on December 31, 2008: 1. It has disclosed a 0% ownership stake in Healthcare Services Group HCSG. It has completely sold out...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 29 Jan 2009 03:51:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/market+folly.html"><![CDATA[Market Folly]]></category>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare+services+group+inc..html"><![CDATA[Healthcare Services Group Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HCSG</category>
		<category domain="tickers">AKRX,HCSG</category>
	</item>
	<item>
		<title><![CDATA[Akorn, Inc. Q3 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-250150.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions We will take our first question from Scott Hirsch with Credit Suisse. Scott Hirsch &#8211; Credit Suisse Good evening guys, how are you? Arthur Przybyl Hi Scott. Scott Hirsch &#8211; Credit Suisse Handful of questions for you. I want to start with the...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 18 Nov 2008 01:01:29 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/hospital.html"><![CDATA[Hospital]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/td.html"><![CDATA[Td]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/hospital.html"><![CDATA[Hospital]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/td.html"><![CDATA[Td]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Nov_3/ai_n30959079]]></link>
		<description><![CDATA[LAKE FOREST, Ill. -- Akorn-Strides, LLC today announced that the U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application ANDA for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2004 by...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 03 Nov 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approvals for Dexamethasone Sodium Phosphate Injection USP, 4 mg /mL and Dexamethasone Sodium Phosphate Injection USP, 10 mg /mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_2/ai_n28048061]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of two ANDAs for Dexamethasone Sodium Phosphate Injection USP, 4 mg base/mL in 1mL, 5 mL, and 30 mL vials, and Dexamethasone Sodium Phosphate Injection USP, 10 mg base/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 02 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn, Inc. Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-223752.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you. Operator instructions We'll go to Noelle Tune with Soleil Securities.  Noelle Tune &#8211; Soleil Securities  Good afternoon, guys, and congratulations on a nice quarter.  Arthur Przybyl  Thank you, Noelle.  Noelle Tune &#8211; Soleil Securities  Appreciate all the transparency...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 25 Aug 2008 09:39:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces the First Commercial Product Launch for the Joint Venture, Rifampin for Injection]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_July_11/ai_n27909138]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the first commercial product launch for the Joint Venture, Rifampin for Injection USP, 600 mg/vial. Rifampin is used in the treatment of all forms of tuberculosis in conjunction with Isoniazid and Ethambutol.  To date, the company has filed for 18 ANDAs...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 11 Jul 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approvals for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and Famotidine Injection USP, 40 mg/4mL & 200 mg/20 mL Multiple-Dose Vials]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_26/ai_n27871185]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approvals of two ANDAs for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and 40 mg/4mL & 200 mg/20mL Multiple-Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE:...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 26 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_23/ai_n25452520]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture.  Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 23 May 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Flumazenil Injection USP, 0.1 mg/mL - 5mL and 10 mL Multiple Dose Vials]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_14/ai_n25411880]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Flumazenil Injection USP, 0.1 mg/mL, packaged in 5 mL and 10 mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ:AKRX) and Strides Arcolab Limited (NSE:STAR) (BSE:532531)....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 May 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
</channel>
</rss>
